<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F1E10788-8795-456D-A1DF-B484F303C6B6"><gtr:id>F1E10788-8795-456D-A1DF-B484F303C6B6</gtr:id><gtr:name>Research and Development AstraZeneca</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F1E10788-8795-456D-A1DF-B484F303C6B6"><gtr:id>F1E10788-8795-456D-A1DF-B484F303C6B6</gtr:id><gtr:name>Research and Development AstraZeneca</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CACE3C60-286D-41DE-B6C8-11ECB4934262"><gtr:id>CACE3C60-286D-41DE-B6C8-11ECB4934262</gtr:id><gtr:firstName>Adrien</gtr:firstName><gtr:surname>Kissenpfennig</gtr:surname><gtr:orcidId>0000-0002-9633-3111</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/626F2738-68F8-4F00-ABA6-B2FE420F7A7C"><gtr:id>626F2738-68F8-4F00-ABA6-B2FE420F7A7C</gtr:id><gtr:firstName>Padraic</gtr:firstName><gtr:surname>Fallon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D231ECC5-D117-4E74-87D7-C1B672E3CB12"><gtr:id>D231ECC5-D117-4E74-87D7-C1B672E3CB12</gtr:id><gtr:firstName>Cecilia</gtr:firstName><gtr:surname>O Kane</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/196A7E43-E653-4989-82D1-8C8054CCD508"><gtr:id>196A7E43-E653-4989-82D1-8C8054CCD508</gtr:id><gtr:firstName>Danny</gtr:firstName><gtr:surname>McAuley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/57AFB11D-B821-480D-94A6-35DF832BD260"><gtr:id>57AFB11D-B821-480D-94A6-35DF832BD260</gtr:id><gtr:firstName>Francois</gtr:firstName><gtr:surname>Fay</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D33C797B-712D-4BDA-841C-D0E6AFE36362"><gtr:id>D33C797B-712D-4BDA-841C-D0E6AFE36362</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Scott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ014680%2F1"><gtr:id>44565B93-EB27-4253-B0ED-B5DDBABDBAF7</gtr:id><gtr:title>Development of a novel anti-inflammatory nanoparticle for the treatment of Acute Lung Injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J014680/1</gtr:grantReference><gtr:abstractText>Acute lung injury is a life threatening and incapacitating condition that affects 20% of all critically ill patients in intensive care. Around 30-50% of these sufferers will die from the condition and many survivors can have serious reductions in the quality of the life with chronic lung problems. This not only has a major effect on the patients themselves, but is also a serious resource allocation problem for the NHS as an ICU bed costs in excess of &amp;pound;1800 per day. There is no effective treatments for this condition at this time and therefore new medicines are urgently needed that can deal and stabilise the condition. ALI is characterised by a vicious cycle of inflammation in the lung that leads to inappropriate infiltration of immune cells to the lung. We have developed a potential treatment for this condition that may have the ability to be nasally delivered to patients in intensive care that has potent anti-inflammatory effects. This treatment is a nano-sized formulation that binds specifically to immunosuppressive receptors found on the surface of immune cells such as macrophages, resulting in significant reduction of the production of inflammatory signaling molecules called cytokines. 

Therefore in this proposal we aim to bring this treatment closer to clinical development by evaluating its effectiveness in a range of preclinical models of ALI. This work will inform us on its effectiveness, side effects and formulation and dosing of the therapeutic required to obtain a significant effect.</gtr:abstractText><gtr:technicalSummary>Acute Lung Injury (ALI) is a serious condition associated with significant morbidity, mortality and healthcare resource utilisation, for which no effective pharmacologic treatment is available. ALI is caused by the uncontrolled activation of immune cells, resulting in an unregulated cycle of inflammation that leads to damage to the alveolar epithelial-endothelial barrier, leading to acute respiratory failure and the need for mechanical ventilation. This is therefore an area of clear unmet clinical need for effective anti-inflammatory therapies.
We have developed a novel nanoparticle which has potent anti-inflammatory effects. Here we will investigate its application in ALI by examining effects in two clinically relevant murine models of ALI (intratracheal LPS and cecal ligation and puncture), ex vivo patient and volunteer alveolar macrophages and a human ex vivo lung perfusion model. This project will provide data on physiological outcomes and toxicity upon administration with our nanoparticle to determine if further development into preclinical trials is warranted.</gtr:technicalSummary><gtr:potentialImpactText>The primary goal of this research in terms of impact is that it will significantly help the outcomes to patients in intensive care that present with ALI. This will therefore no only impact them, but carers and also then resource allocation within the health service of the UK (and internationally).

In addition to this condition, the anti-inflammatory effects of the modality make it amenable to the treatment of other conditions underpinned by inappropriate inflammation, both in the lung and in other parts of the body. With this in mind, this research is likely to impact other researchers both academically and industrially in development of follow-on therapeutics and biomaterials that can exploit these effects. Therefore it is tangible that if successful, this project could lead on to the development of other daughter therapeutics that could not only help patients suffering other inflammatory diseases, but also generate new R &amp;amp; D jobs and revenue for the UK.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>531067</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research and Development AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Toxicology Sciences</gtr:department><gtr:description>project into pulmonary nanoparticle toxicity</gtr:description><gtr:id>313000AC-3F08-462B-90BB-B301FBCBE0C4</gtr:id><gtr:impact>Invited lecture - Visualisation of nanoparticle induced toxicty using protease signatures - Tiers Winter School on proteolysis in Feb 2013</gtr:impact><gtr:partnerContribution>Have supplied expertise and will provide models to examine the methodologies that we produce in the next couple of years</gtr:partnerContribution><gtr:piContribution>We have used our technology and expertise gained during this research project to develop a new research angle that is important in both understanding nanoparticle deposition and monitoring of adverse effects</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Research GSK</gtr:department><gtr:description>developed relationship with GSK on basis of this project</gtr:description><gtr:id>485E0C5A-EE5F-4D71-BE17-542F0A9E70C0</gtr:id><gtr:impact>Royal Society Industrial Fellowship awarded</gtr:impact><gtr:partnerContribution>compounds shared for evaluation</gtr:partnerContribution><gtr:piContribution>Evaluation of technology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>RCUK teacher training</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AF1C613F-E4BB-448B-89D0-36E9DD4B1641</gtr:id><gtr:impact>Used the opportunity to refresh teachers knowledge of rapidly developing areas, highlighting our own research interests and education about the requirement for animal usage in research

Invites to schools to talk about research ongoing at QUB</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FA39F313-8E83-4F58-8769-2489CDA4770C</gtr:id><gtr:impact>30 puils who are interested in undertaking careers with biology background in a career session

invited to take part in session again</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nanoparticle Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0AF4C49E-5E1C-4C75-BAE9-EA0DA5B729FD</gtr:id><gtr:impact>International press release made by QUB in conjunction with MRC

Several companies have now approached us about the innovation and patient groups. More engagement anticipated from this in the future 12 months</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters, Northern Ireland</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>24E9BDFE-D264-4A71-A849-94D4344E7E3C</gtr:id><gtr:impact>Acted as judge for the session of three schhools - approx 20 pupils and teachers

Have been asked to take part in a RCUK-led schools teacher training event</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.debatingmatters.com/events/qr/northern_ireland_south_2013_14/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ERS Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F02C95B3-303B-42ED-87C6-CB4616E2CF14</gtr:id><gtr:impact>Invited speaker at the European Respiratory Society Meeting special section on nanotechnology. &amp;quot;Development of a novel nanomedicine for the treatment of Acute Lung Injury' speaker - Chris Scott; Spet 2013, Barcelona

Potential industrial collaborator has come forward and initial talks on the technology have now been undertaken</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://ersnet.org/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture British Society of Nanomedicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9BBEA8E3-6164-4AD0-8C50-8745756906BB</gtr:id><gtr:impact>Keynote lecture at the young researchers meeting in Swansea</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRS Boston</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8DC9E1BA-49B4-4D85-8058-CCFDEA64D391</gtr:id><gtr:impact>Invited speech at the Fall MRS meeting in Boston 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SialoGlyco meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1D799901-049F-487F-9D10-C21127466049</gtr:id><gtr:impact>Gave a invited lecture at this meeting in California. Stimulated interest in our new drug modality from interested companies in USA, and Japan</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Industrial Fellowship</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>AD6CF484-BD96-4FD5-883E-B795AB04F122</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel technology for the targeting and activation of inhibitory Siglec receptors to block inflammation</gtr:description><gtr:id>826F141C-2746-4A44-A054-4BA3B9669EC4</gtr:id><gtr:impact>Demonstrated efficacy now in models of sepsis and acute respiratory distress syndrome</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO 2011073685 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Modulator</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Trustee of the new British Society of Nanomedicine</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5031C7AA-7708-4BE4-B757-E1E5E4F56C77</gtr:id><gtr:impact>The mission of the British Society of Nanomedicine to to educate scientists and general public on the role of nano medicine in health and to remove some of the misconceptions that arise in public perception. The Society represents the national body of nano medicine in the UK, is associated with its European partners to strive in the improvement of health using nanotechnology</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.britishsocietynanomedicine.org</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF850C28-B4A3-4904-A1B2-3713D46F2E72"><gtr:id>CF850C28-B4A3-4904-A1B2-3713D46F2E72</gtr:id><gtr:title>Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7031cecc38b223f89a0d7e28f9a20c11"><gtr:id>7031cecc38b223f89a0d7e28f9a20c11</gtr:id><gtr:otherNames>Spence S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J014680/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>